Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors

References

• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: Past, present, and future. J Clin Invest. 2006; 116 11: 2843–2854.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000; 23 4: 453–477.
   Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001; 357 9274: 2122–2128.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Einarson BL, Lennon VA, Seybold ME. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. J Exp Med. 1976; 144 3: 726–738.
   Google Scholar
• Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973; 180 88: 871–872.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med. 1976; 144 3: 739–753.
   PubMed Web of Science ®Google Scholar
• Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 1987; 15 2: 185–194.
   Web of Science ®Google Scholar
• Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron. 1995; 15 2: 323–331.
   Google Scholar
• Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998; 163:89–120.
   PubMed Web of Science ®Google Scholar
• Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA. 1982; 79 1: 188–192.
   Google Scholar
• Saedi MS, Anand R, Conroy WG, Lindstrom J. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett. 1990; 267 1: 55–59.
   Google Scholar
• Conroy WG, Saedi MS, Lindstrom J. TE671 cells express an abundance of a partially mature acetylcholine receptor α subunit which has characteristics of an assembly intermediate. J Biol Chem. 1990; 265 35: 21642–21651.
   Google Scholar
• Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci. 2009; 29 44: 13898–13908.
   Google Scholar
• Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature. 2001; 411 6835: 269–276.
   PubMed Web of Science ®Google Scholar
• Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y. Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. Embo J. 2005; 24 20: 3635–3646.
   PubMed Web of Science ®Google Scholar
• Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J Mol Biol. 2005; 346 4: 967–989.
   PubMed Web of Science ®Google Scholar
• Luo J, Kuryatov A, Lindstrom JM. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism. Ann Neurol. 2010; 67 4: 441–451.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Lennon VA, Seybold ME, Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: Biochemical and immunochemical aspects. Ann NY Acad Sci. 1976; 274:254–274.
   PubMedGoogle Scholar
• Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: Cellular and humoral immune responses. Ann NY Acad Sci. 1976; 274:283–299.
   PubMed Web of Science ®Google Scholar
• Kuryatov A, Luo J, Cooper J, Lindstrom J. Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol. 2005; 68 6: 1839–1851.
   Google Scholar
• Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, Lindstrom J. Chronic nicotine treatment up-regulates human α3β2 but not α3β4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem. 1998; 273 44: 28721–28732.
   Google Scholar
• Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P, De Baets MH, Martinez-Martinez P. The auto-antigen repertoire in myasthenia gravis. Autoimmunity. 2010; 43 5–6: 380–400.
   Web of Science ®Google Scholar
• Shelton GD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology. 1988; 38 9: 1417–1423.
   Google Scholar
• Tzartos S, Langeberg L, Hochschwender S, Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett. 1983; 158 1: 116–118.
   Google Scholar
• Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol. 1985; 134 4: 2343–2349.
   Google Scholar
• Hoyer LW, Trabold NC. The significance of erythrocyte antigen site density. II. Hemolysis. J Clin Invest. 1971; 50 9: 1840–1846.
   Google Scholar
• Wong JT, Colvin RB. Bi-specific monoclonal antibodies: Selective binding and complement fixation to cells that express two different surface antigens. J Immunol. 1987; 139 4: 1369–1374.
   Google Scholar
• Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol. 1998; 110 2: 103–109.
   PubMed Web of Science ®Google Scholar
• Feferman T, Im SH, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2003; 140 1–2: 153–158.
   Google Scholar
• Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Adv Neuroimmunol. 1994; 4 4: 373–386.
   Google Scholar
• Moulian N, Wakkach A, Guyon T, Poea S, Aissaoui A, Levasseur P, Cohen-Kaminsky S, Berrih-Aknin S. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann NY Acad Sci. 1998; 841:397–406.
   PubMedGoogle Scholar
• Deitiker P, Ashizawa T, Atassi MZ. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis?. Hum Immunol. 2000; 61 3: 255–265.
   Google Scholar